The effect of etidronate disodium (EHDP) on retinopathy in insulin-dependent diabetic patients.
In a randomized double-blind study the effect of etidronate disodium (EHDP) on retinopathy, plasma inorganic phosphate and blood oxygen transport was assessed in 26 insulin-dependent diabetic patients. Following 6 months of EHDP administration, plasma inorganic phosphate had increased significantly (1.48 vs 1.14 mmol/l; P less than 0.01). Red cell, 2,3-diphosphoglycerate concentration (16.9 vs 15.1 mumol/g Hb; P less than 0.01) and the haemoglobin-oxygen affinity measured by pO2 at 50% oxygen saturation (P50) had also increased significantly (27.5 vs 26.3 mmHg; P less than 0.01). No changes had occurred in mean blood glucose and haemoglobin A1c concentrations, indicating a comparable degree of glucose regulation. Following 6 months of EHDP administration an association was found between improvement in retinopathy and the increase in plasma inorganic phosphate.
D019794:2,3-Diphosphoglycerate; D000328:Adult; D001786:Blood Glucose; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D004163:Diphosphoglyceric Acids / Q000097:blood; D004311:Double-Blind Method; D012968:Etidronic Acid / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010101:Oxygen Consumption; D010313:Partial Pressure; D010710:Phosphates / Q000097:blood; D011897:Random Allocation
D001786:Blood Glucose; D004163:Diphosphoglyceric Acids; D010710:Phosphates; D019794:2,3-Diphosphoglycerate; D012968:Etidronic Acid